Brief: Xencor Inc - Caris Life Sciences And Xencor Enter Target Discovery Collaboration And License Agreement For Novel XmAb Bispecific Antibodies

Xencor

02/08/2022 12:09

Aug 2 (Reuters) - Xencor Inc  XNCR.O :
    * XENCOR INC - CARIS LIFE SCIENCES AND XENCOR ENTER TARGET
DISCOVERY COLLABORATION AND LICENSE AGREEMENT FOR NOVEL XMAB
BISPECIFIC ANTIBODIES
    * CARIS LIFE SCIENCES - WILL APPLY PROPRIETARY END-TO-END
DISCOVERY PLATFORM TO IDENTIFY NOVEL TARGETS FOR BISPECIFIC
ANTIBODY DRUG CANDIDATES
    * XENCOR INC - XENCOR WILL RECEIVE EXCLUSIVE OPTIONS TO
RESEARCH,
DEVELOP AND COMMERCIALIZE PRODUCTS DIRECTED TO UP TO THREE
TARGETS
    * XENCOR INC - CARIS TO RECEIVE UPFRONT PAYMENT AND BE
ELIGIBLE TO
RECEIVE UP TO ABOUT $120 MILLION

Source text for Eikon:  ID:nPn1rdrCDa 
Further company coverage:  XNCR.O 

 ((Reuters.Briefs@thomsonreuters.com;))